EHA 2018 | ENESTop: deep molecular response in CML can be translated into treatment-free remission

Timothy Hughes

Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an overview of the follow-up study of ENESTcmr. The ENESTop trial (NCT01698905) was designed to address whether deep molecular response in chronic myeloid leukemia (CML) could be translated into treatment-free remission (TFR). Over 50% of patients who started on imatinib and had switched to nilotinib remained in TFR. This suggests that switching a patient onto a diffeent tyrosine kinase inhibitor, in order to achieve a deaper response, will eventually translate into acheiving higher rates of TFR. This video was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.

Share this video